Atrial fibrillation and MPN patients with Jak2 mutation
A recently published research article may be of interest to MPN patients with the Jak2 mutation. It is titled ‘Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2V617F-Positive Myeloproliferative Neoplasms‘. The article was published in Cancer Medicine in July 2025.
The researchers retrospectively analysed clinical profiles of 439 Chinese MPN patients with the Jak2 mutation from several hospitals in China between 2017 and March 2025. The researchers’ intention was to consider specific risk factors for atrial fibrillation (AF) in the MPN patient population which they felt “have not been fully elucidated”.
The researchers concluded that:
- “atrial fibrillation was significantly associated with higher risks of stroke and mortality in patients with JAK2V617F-positive MPN.
- TET2 mutation and increased IL-1ß were independent risk factors of AF in patients with JAK2V617F-positive MPN.”
- They also noted that “interferon-alfa and ruxolitinib were associated with improved AF-free survival in patients in the high-risk group.”
The paper is freely available to read in full HERE.
International review series on MPNs published
The April 2025 edition of Haematologica features an excellent review series on MPNs.
The authors of the introduction paper to the series, Australia’s Drs Steven Lane and Yin Yuan, explain that ‘the review series is not designed to be a definitive review of all aspects of MPN biology and treatment. Rather, we have selected a few key topics of particular interest to the field that have been informed by recent advances in basic or clinical research’.
In addition to the paper from Drs Steven Lane and Yin Yuan, paper no 4, ‘Pathogenesis and management of high molecular risk myeloproliferative neoplasms’ also features two Australian coauthors, haematologist and researcher Dr Victoria Ling and researcher Dr Megan Bywater.
The papers are all free to access and linked below:
- Prevention, diagnosis and management of myeloproliferative neoplasms: an introduction to a review series,
- Evolution of myeloproliferative neoplasms from normal blood stem cells,
- ‘Clinical and laboratory approaches to target and eradicate early disease-initiating stem cells’:
Paper is titled New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-a alter the natural history of the disease?, - Pathogenesis and management of high molecular risk myeloproliferative neoplasms,
- ‘Strategies to prevent or treat the devastating clinical consequence of AML arising from antecedent MPN, also known as blast-phase MPN’. Paper is titled Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia.
The MPN Alliance Australia works in partnership with the Leukaemia Foundation
